Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: luis a. garcia who wrote (816)	1/8/1998 10:23:00 AM
From: M.LUTH	Read Replies (2) \| Respond to of 1115

Luis, didn't Lidak do a trial comparing Lidakol with Zovirax? I am trying to remember if they did or not, I seem to remember they did and Lidakol performed better than Zovirax. If that is the case wouldn't the FDA take that into consideration when approving. If Lidakol performs better than the only other drug out there I would think it would be in Lidak's benefit for approval. All the other stuff everybody is talking about p number on this board and the Yahoo board would have little significance. Can you clear this up for me. Mike

To: luis a. garcia who wrote (816)	1/8/1998 11:29:00 AM
From: Henry Volquardsen	Read Replies (1) \| Respond to of 1115

however the speculation is that BMY is in biz to make money for them not for LDAKA and the margin may not have been exciting enough for them hmmmm! If the margin's are not that exciting for BMY could that be an indication that Lidakol may not be a prescription drug but may go over the counter instead? We speculated on that last year in regards to Lidakol being non mutagenic. Just speculating here but that could be very interesting. What if Lidak licenses to someone with more of a consumer products focus?